Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Abroad (travel likely)RecruitingPHASE1

Conditions

Cervical Cancer · Breast Cancer · Colon Cancer · NSCLC · mCRPC (Metastatic Castration-resistant Prostate Cancer) · Glioblastoma · Nonsmall Cell Lung Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Northwestern University Robert H Lurie Medical Research, Chicago, Illinois, United States

  • University of Iowa Health Care, Iowa City, Iowa, United States

    Contact: Principal Investigator (David Bushness, MD)
  • UK Markey Cancer Center, Lexington, Kentucky, United States

    Study coordinator · 859-323-7628
    Contact: Principal Investigator (Eddy Yang, MD)
  • Advanced Molecular Imaging and Therapy, Glen Burnie, Maryland, United States

    Study coordinator · 443-333-1894
    Contact: Principal Investigator (Michael Morris, MD)
  • United Theranostics - Chesapeake, Glen Burnie, Maryland, United States

    Contact: Principal Investigator (Babak Saboury, MD)
  • Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha, Nebraska, United States

    Contact: Principal Investigator (Samuel Mehr, MD)
  • XCancer Omaha / Urology Cancer Center, Omaha, Nebraska, United States

    Study coordinator · 402-697-2229
    Contact: Principal Investigator (Luke Nordquist, MD)
  • University of Pittsburg Medical Center (UPCM), Pittsburgh, Pennsylvania, United States

    Contact: Principal Investigator (Neeta Pandit Taskar, MD)